Enhancing active immunity against hepatitis B virus by HBV vaccine immunization in patients with HBV-related end-stage liver diseases treated with liver transplantation.
- Author:
Sheng-jie JIN
1
;
Shi-chun LU
;
Wei LAI
;
Jun DAI
;
Ji ZHAO
;
You-ping LI
;
Lü-nan YAN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Female; Hepatitis B; immunology; Hepatitis B Vaccines; therapeutic use; Hepatitis B virus; Humans; Immunity, Active; Liver Diseases; immunology; virology; Liver Transplantation; Male; Middle Aged; Postoperative Period
- From: Chinese Journal of Hepatology 2008;16(4):261-264
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo study the active immunity response of liver transplant patients for HBV-related diseases after hepatitis B virus (HBV) vaccine immunization and to investigate the factors that influence the effectiveness of the vaccination in order to find measures to increase its success.
METHODSThirteen patients who had liver transplants because of HBV-related end-stage liver diseases received hepatitis B virus immunoglobulin and lamivudine for an average of 38 months (range 27-77 months). They received double intramuscular doses (40 microg) of a recombinant vaccine at months 0, 1, 2 and 6. The anti-HBs titers were tested regularly at months 1, 2, 3, 6 and 7.
RESULTSSeven of the 13 patients (53.8%) developed higher serum titers of anti-HBs compared with their titers prior to the vaccinations, 2 patients of the 13 (15.4%) developed an increase by 100 U/L and in 4 patients (30.8%) their base levels were doubled. Those responding patients were followed-up for another 8 months after the fourth vaccination, and only 1 patient among them had a decrease of the anti-HBs titers below the level prior to the vaccination.
CONCLUSIONHepatitis B vaccine immunization can be used to enhance the active immunity against HBV in patients who had liver transplants for HBV-related diseases.